What makes a patient a good candidate for treatments targeting amyloid such as lecanemab or donanemab?
Are there patients in whom you would specifically avoid this class of treatments?
Community PollStarted
In which patients will you avoid using anti-amyloid therapies?
41 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Neurology · Baylor College of Medicine
Answered on
All the amyloid antibody trials were conducted in patients without the burden of cerebrovascular disease we often see in clinic populations. Many individuals with cognitive impairment have both vascular and neurogenerative contributions to their decline. We don’t yet know from real-world experience ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Neurology · The University of Virginia
Answered on
Lecanemab and donanemab were studied in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease. Confirmation with biomarkers and exclusion of other possible causes of dementia is required.
Join for free or sign in to see the full answer